Background: Irritable bowel syndrome (IBS) is a functional bowel disorder which is characterized by abdominal pain and disturbed bowel habits. The pathophysiological mechanism is complex and still remains incompletely clear. Alterations at both the central and the peripheral level are thought to contribute to the symptoms of IBS, including psychosocial factors, visceral hypersensitivity and abnormal gastrointestinal motility and secretion. Several gut peptides contribute to the regulation of gastrointestinal function, but little is known about gut hormone secretion in IBS. Methods: We evaluated the concentrations of cholecystokinin (CCK), vasoactive intestinal peptide (VIP), somatostatin, substance P, neuropeptide Y (NPY) in plasma and in sigmoid tissue in 40 patients with IBS and 15 age- and gender-matched controls by using radioimmunoassay. Results: IBS patients had higher plasma level of CCK (p < 0.01), and the level of CCK in the sigmoid was also increased compared with controls (p < 0.05). The levels of somatostatin and substance P in fasting plasma and in the sigmoid were not different between IBS patients and control subjects (p > 0.05), but the levels of VIP in sigmoid tissue or in plasma were higher in IBS patients than in control group (p < 0.01). The NPY levels in both plasma and the sigmoid were significantly lower in IBS patients than in controls (p < 0.05). Plasma NPY level in patients with IBS with diarrhea as a predominant bowel pattern was lower than in patients with IBS with constipation as a predominant bowel pattern. Conclusion: IBS patients have increased levels of CCK and VIP and decreased NPY levels in fasting plasma and sigmoid tissue. These alterations of VIP, CCK and NPY may play a role in the pathogenesis of IBS.

1.
Rodriguez LA, Ruig&oacute;mez A: Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999;318:565&ndash;566.
[PubMed]
2.
Gonsalkorale WM, Perrey C, Pravica V, Whorwell PJ, Hutchinson IV: Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91&ndash;93.
[PubMed]
3.
Gupta V, Sheffield D, Verne GN: Evidence for autonomic dysregulation in the irritable bowel syndrome. Dig Dis Sci 2002;47:1716&ndash;1722.
[PubMed]
4.
Verne GN, Himes NC, Robinson ME, Gopinath KS, Briggs RW, Crosson B, Price DD: Central representation of visceral and cutaneous hypersensitivity in the irritable bowel syndrome. Pain 2003;103:99&ndash;110.
[PubMed]
5.
Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995;109:40&ndash;52.
[PubMed]
6.
Chey WY, Jin HO, Lee MH, Sun SW, Lee KY: Colonic motility abnormality in patients with irritable bowel syndrome exhibiting abdominal pain and diarrhea. Am J Gastroenterol 2001;96:1499&ndash;1506.
[PubMed]
7.
Kleibeuker JH, Beekhuis H, Jansen JB, Piers DA, Lamers CB: Cholecystokinin is a physiological hormonal mediator of fat-induced inhibition of gastric emptying in man. Eur J Clin Invest 1988;18:173&ndash;177.
[PubMed]
8.
Niederau C, Faber S, Karaus M: Cholecystokinin&rsquo;s role in regulation of colonic motility in health and in irritable bowel syndrome. Gastroenterology 1992;102:1889&ndash;1898.
[PubMed]
9.
Sabate JM, Gorbatchef C, Flourie B, Jian R, Coffin B: Cholecystokinin octapeptide increases rectal sensitivity to pain in healthy subjects. Neurogastroenterol Motil 2002;14:689&ndash;695.
[PubMed]
10.
Zhou L, Ke MY: Gastrointestinal Motility &ndash; Basic and Clinical Medicine. Beijing, Beijing Science Publishing Company, 1999, pp 140&ndash;142.
11.
Kusano M, Sekiguchi T, Kawamura O, Kikuchi K, Miyazaki M, Tsunoda T, Horikoshi T, Mori M: Further classification of dysmotility-like dyspepsia by interdigestive gastroduodenal manometry and plasma motilin level. Am J Gastroenterol 1997;92:481&ndash;484.
[PubMed]
12.
Dong WZ, Zou DW, Li ZS, Zou XP, Zhu AY, Xu GM, Yin N, Gong YF, Sun ZX, Man XH: Study of visceral hypersensitivity in irritable bowel syndrome. Chin J Dig Dis 2004;5:103&ndash;109.
[PubMed]
13.
Sj&ouml;qvist A, Fahrenkrug J, Jodal M, Lundgren O: The effect of splanchnic nerve stimulation and neuropeptide Y on cholera secretion and release of vasoactive intestinal polypeptide in the feline small intestine. Acta Physiol Scand 1988;133:289&ndash;295.
[PubMed]
14.
Simr&eacute;n M, Abrahamsson H, Bj&ouml;rnsson ES: An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001;48:20&ndash;27.
[PubMed]
15.
Zhang ZB, Zhang XY, Den JL, Hu JL, Zhang HB, Lian JQ, et al: Preliminary studies on substance P and vasoactive intestinal polypeptide in ulcerative colitis, chronic colitis and irritable bowel syndrome. Biomed Res Tokyo 1992;13(suppl 2):275&ndash;278.
16.
Sj&ouml;lund K, Fasth S, Ekman R, Hult&eacute;n L, Jiborn H, Nordgren S, Sundler F: Neuropeptides in idiopathic chronic constipation. Neurogastroenterol Motil 1997;9:143&ndash;150.
[PubMed]
17.
Lysy J, Karmeli F, Sestieri M, Yatzkan Y, Goldin E: Decreased substance P content in the rectal mucosa of diabetics with diarrhea and constipation. Metabolism 1997;46:730&ndash;734.
[PubMed]
18.
Simr&eacute;n M, Stotzer PO, Sj&ouml;vall H, Abrahamsson H, Bj&ouml;rnsson ES: Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2003;15:55&ndash;62.
[PubMed]
19.
Wu HG, Jiang B, Zhou EH, Shi Z, Shi DR, Cui YH, Kou ST, Liu HR: Regulatory mechanism of electroacupuncture in irritable bowel syndrome: preventing MC activation and decreasing SP VIP secretion. Dig Dis Sci 2008;53:1644&ndash;1651.
[PubMed]
20.
Morise K, Furusawa A, Yamamoto H, Saito H: Role of gut hormones in irritable bowel syndrome. Nippon Rinsho 1992;50:2697&ndash;2702.
[PubMed]
21.
Waldman DB, Gardner JD, Zfass AM, Makhlouf GM: Effects of vasoactive intestinal peptide, secretin, and related peptides on rat colonic transport and adenylate cyclase activity. Gastroenterology 1977;73:518&ndash;523.
[PubMed]
22.
Barbezat GO, Grossman MI: Intestinal secretion: stimulation by peptides. Science 1971;174:422&ndash;424.
[PubMed]
23.
Krejs GJ, Fordtran JS, Bloom SR, Fahrenkrug J, Schaffalitzky de Muckarell OB, Fisher JE, Humphrey CS, O&rsquo;Dorisio TM, Said SI, Walsh JH, Shulkes AA: Effect of VIP infusion on water and ion transport in the human jejunum. Gastroenterology 1980;78:722&ndash;727.
[PubMed]
24.
Biancani P,Walsh JH, Behar J: Vasoactive intestinal-polypeptide: a neurotransmitter for relaxation of the rabbit internal anal sphincter. Gastroenterology 1985;89:867&ndash;874.
[PubMed]
25.
De Beurme FA, Lefebvre RA: Vasoactive intestinal polypeptide as possible mediator of relaxation in the rat gastric fundus. J Pharm Pharmacol 1988;40:711&ndash;715.
[PubMed]
26.
Goyal RK, Rattan S, Said SI: VIP as a possible neurotransmitter of non-cholinergic non-adrenergic inhibitory neurons. Nature 1980;288:378&ndash;380.
[PubMed]
27.
Grider JR: Identification of neurotransmitters regulating intestinal peristaltic reflex in humans. Gastroenterology 1989;97:1414&ndash;1419.
[PubMed]
28.
Koch TR, Carney JA, Go L, Go VL: Idiopathic chronic constipation is associated with decreased colonic vasoactive intestinal peptide. Gastroenterology 1988;94:300&ndash;310.
[PubMed]
29.
Milner P, Crowe R, Kamm MA, Lennard-Jones JE, Burnstock G: Vasoactive intestinal polypeptide levels in sigmoid colon in idiopathic constipation and diverticular disease. Gastroenterology 1990;99:666&ndash;675.
[PubMed]
30.
Koch TR, Mitchener SR, Go VL: Plasma vasoactive intestinal polypeptide concentration determined in patients with diarrhea. Gastroenterology 1991;100:99&ndash;106.
[PubMed]
31.
Palsson OS, Morteau O, Bozymski EM, Woosley JT, Sartor RB, Davies MJ, Johnson DA, Turner MJ, Whitehead WE: Elevated vasoactive intestinal peptide concentrations in patients with irritable bowel syndrome. Dig Dis Sci 2004;49:1236&ndash;1243.
[PubMed]
32.
Van Der Veek PP, Biemond I, Masclee AA: Proximal and distal gut hormone secretion in irritable bowel syndrome. Scand J Gastroenterol 2006;41:170&ndash;177.
[PubMed]
33.
Yaozhong Y: Irritable Bowel Syndrome. Shanghai, Shanghai Science Press, 2002, pp 46&ndash;47.
34.
Holzer-Petsche U, Petritsch W, Hinterleitner T, Eherer A, Sperk G, Krejs GJ: Effect of neuropeptide Y on jejunal water and ion transport in humans. Gastroenterology 1991;101:325&ndash;330.
[PubMed]
35.
Arzubiaga C, Morrow J, Roberts LJ 2nd, Biaggioni I: Neuropeptide Y, a putative cotransmitter in noradrenergic neurons, induces mast cell degranulation but not prostaglandin D2 release. J Allergy Clin Immunol 1991;87:88&ndash;93.
[PubMed]
You do not currently have access to this content.